ReviewCNS drugs2017
Narcolepsy Type 1 as an Autoimmune Disorder: Evidence, and Implications for Pharmacological Treatment.
Review in CNS drugs, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06336057 (Mentalizating in Adults Suffering from Narcolepsy Type 1, a Comparative Prospective Study.), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Mentalizating in Adults Suffering from Narcolepsy Type 1, a Comparative Prospective Study.
Who cites it
13 citing papers in PubMed, 41 citations in OpenAlex.
- Attention and inhibition deficits in narcolepsy type 1: behavioral and electrophysiological markers.Translational psychiatry · 2025Article
- Present and Future of Central Disorders of Hypersomnolence.Journal of sleep research · 2025Review
- The immunopathogenesis of narcolepsy type 1.Nature reviews. Immunology · 2024Review
- A series of 7 cases of patients with narcolepsy with hypocretin deficiency without the HLA DQB1*06:02 allele.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2023Article
- LC-MS/MS-Based Proteomics Approach for the Identification of Candidate Serum Biomarkers in Patients with Narcolepsy Type 1.Biomolecules · 2023Article
- Comorbid parasomnias in narcolepsy and idiopathic hypersomnia: more REM than NREM parasomnias.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2022Article
- Histamine in murine narcolepsy: What do genetic and immune models tell us?Brain pathology (Zurich, Switzerland) · 2022Article
- Gut microbiota composition is associated with narcolepsy type 1.Neurology(R) neuroimmunology & neuroinflammation · 2020Article
- Recently Approved and Upcoming Treatments for Narcolepsy.CNS drugs · 2020Review
- Analyzing Functional Pathways and constructing gene-gene network for Narcolepsy based on candidate genes.International journal of medical sciences · 2020Article
- Recent advances in treatment for narcolepsy.Therapeutic advances in neurological disorders · 2019Review
- Immune-mediated comorbidities in Saudi patients with narcolepsy.Nature and science of sleep · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Narcolepsy type 1 (NT1) is a rare sleep disorder caused by the very specific loss of hypothalamic hypocretin (Hcrt)/orexin neurons. The exact underlying process leading to this destruction is yet unknown, but indirect evidence strongly supports an autoimmune origin. The association with immune-related genetic factors, in particular the strongest association ever reported in a disease with an allele of a human leukocyte antigen (HLA) gene, and with environmental factors (i.e., the H1N1 influenza infection and vaccination during the pandemic in 2009) are in favor of such a hypothesis. The loss of Hcrt neurons is irreversible, and NT1 is currently an incurable and disabling condition. Patients are managed with symptomatic medication, targeting the main symptoms (excessive daytime sleepiness, cataplexy, disturbed nocturnal sleep), and they require a lifelong treatment. Improved diagnostic tools, together with an increased understanding of the pathogenesis of NT1, may lead to new therapeutic and even preventive interventions. One future treatment could include Hcrt replacement, but this neuropeptide does not cross the blood-brain barrier. However, Hcrt receptor agonists may be promising candidates to treat NT1. Another option is immune-based therapies, administered at disease onset, with already some initiatives to slow down or stop the dysimmune process. Whether immune-based therapy could be beneficial in NT1 remains, however, to be proven.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.